Literature DB >> 15843167

Doxorubicin induces EGF receptor-dependent downregulation of gap junctional intercellular communication in rat liver epithelial cells.

Kotb Abdelmohsen1, Claudia von Montfort, Dominik Stuhlmann, P Arne Gerber, Ulrich K M Decking, Helmut Sies, Lars-Oliver Klotz.   

Abstract

Exposure of rat liver epithelial cells to doxorubicin, an anthraquinone derivative widely employed in cancer chemotherapy, led to a dose-dependent decrease in gap junctional intercellular communication (GJC). Gap junctions are clusters of inter-cellular channels consisting of connexins, the major connexin in the cells used being connexin-43 (Cx43). Doxorubicin-induced loss of GJC was mediated by activation of extracellular signal-regulated kinase (ERK)-1 and ERK-2, as demonstrated using inhibitors of ERK activation. Furthermore, activation of the epidermal growth factor (EGF) receptor by doxorubicin was responsible for ERK activation and the subsequent attenuation of GJC. Inhibition of GJC, however, was not by direct phosphorylation of Cx43 by ERK-1/2, whereas menadione, a 1,4-naphthoquinone derivative that was previously demonstrated to activate the same EGF receptor-dependent pathway as doxorubicin, resulting in downregulation of GJC, caused strong phos-phorylation of Cx43 at serines 279 and 282. Thus, ERK-dependent downregulation of GJC upon exposure to quinones may occur both by direct phosphorylation of Cx43 and in a phosphorylation-independent manner.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15843167     DOI: 10.1515/BC.2005.027

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  7 in total

1.  Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients.

Authors:  Peter Arne Gerber; Stephan Meller; Tatiana Eames; Bettina Alexandra Buhren; Holger Schrumpf; Sonja Hetzer; Laura Maximiliane Ehmann; Wilfried Budach; Edwin Bölke; Christiane Matuschek; Andreas Wollenberg; Bernhard Homey
Journal:  Eur J Med Res       Date:  2012-02-23       Impact factor: 2.175

Review 2.  Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.

Authors:  James A McCubrey; Linda S Steelman; William H Chappell; Stephen L Abrams; Ellis W T Wong; Fumin Chang; Brian Lehmann; David M Terrian; Michele Milella; Agostino Tafuri; Franca Stivala; Massimo Libra; Jorg Basecke; Camilla Evangelisti; Alberto M Martelli; Richard A Franklin
Journal:  Biochim Biophys Acta       Date:  2006-10-07

3.  Bilirubin Improves Gap Junction to Alleviate Doxorubicin-Induced Cardiotoxicity by Regulating AMPK-Axl-SOCS3-Cx43 Axis.

Authors:  Siqi Zhang; Yixin Fan; Binbin Zheng; Yu Wang; Chen Miao; Yue Su; Kun Li; Yan E; Xueli Wang; Xueming He; Xuefeng Wu; Chenjie Xu; Yulin Tang; Wen-Tao Liu; Xiangqing Kong; Liang Hu
Journal:  Front Pharmacol       Date:  2022-04-25       Impact factor: 5.988

4.  The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer.

Authors:  Meredith A Morgan; Leslie A Parsels; Laura E Kollar; Daniel P Normolle; Jonathan Maybaum; Theodore S Lawrence
Journal:  Clin Cancer Res       Date:  2008-08-15       Impact factor: 12.531

5.  HuR regulates gap junctional intercellular communication by controlling beta-catenin levels and adherens junction integrity.

Authors:  Niloofar Ale-Agha; Stefanie Galban; Christiane Sobieroy; Kotb Abdelmohsen; Myriam Gorospe; Helmut Sies; Lars-Oliver Klotz
Journal:  Hepatology       Date:  2009-11       Impact factor: 17.425

Review 6.  Redox regulation of FoxO transcription factors.

Authors:  Lars-Oliver Klotz; Cristina Sánchez-Ramos; Ignacio Prieto-Arroyo; Pavel Urbánek; Holger Steinbrenner; Maria Monsalve
Journal:  Redox Biol       Date:  2015-07-03       Impact factor: 11.799

7.  Novel Anticancer Platinum(IV) Complexes with Adamantylamine: Their Efficiency and Innovative Chemotherapy Strategies Modifying Lipid Metabolism.

Authors:  Alois Kozubík; Alena Vaculová; Karel Soucek; Jan Vondrácek; Jaroslav Turánek; Jirina Hofmanová
Journal:  Met Based Drugs       Date:  2008
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.